Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 6 (LILRA6), also known as ILT8 or CD85b, is an activating myeloid receptor that plays a critical role in regulating innate immune responses. Because of its high sequence homology with the inhibitory receptor LILRB3, LILRA6 is a pivotal target for fine-tuning myeloid cell activation in oncology and autoimmune disease research. Developing therapeutics requires highly specific reagents to differentiate between activating and inhibitory LILR pathways.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LILRA6 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LILRA6 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View LILRA6 Products |
| Gene Delivery | LILRA6 Lentivirus Premade Particles Full-length ORF for stable cell line construction and cell-based activation assays. |
View LILRA6 Products |
| Benchmark Ab | Anti-LILRA6 Recombinant Antibody High-affinity positive control for binding and flow cytometry validation. |
View LILRA6 Products |
| Validator | LILRA6 siRNA Set Target-specific knockdown pool for functional validation in primary myeloid cells. |
View LILRA6 Products |
| Related Target A | LILRB3 Highly homologous inhibitory counterpart (>95% ECD sequence identity); essential for counter-screening and selectivity profiling. |
View LILRB3 Products |
| Related Target B | LILRB1 Inhibitory myeloid checkpoint; evaluated alongside LILRA6 to map broader LILR family cross-reactivity. |
View LILRB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| LILRA6 vs. LILRB3 Selectivity | Human LILRA6 and LILRB3 recombinant proteins strictly validated by mass spectrometry to guarantee sequence identity and sequence-level differentiation. |
| Conformational Integrity for Binding | HEK293 mammalian expression host ensures correct post-translational modifications and native folding, preventing false negatives in antibody screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as in-house assay controls. |
| False Positives | High-efficiency siRNA validation sets for gene knockdown confirmation in target cells. |
Live LILRA6 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the LILR family is rapidly expanding, with major pharmaceutical players shifting focus from traditional T-cell checkpoints to myeloid-derived immunosuppressive networks. While first-generation myeloid therapies target LILRB1 and LILRB2, the next wave of drug discovery is focused on the LILRB3/LILRA6 axis. Due to the high sequence similarity between the activating LILRA6 and the inhibitory LILRB3, the strategic challenge lies in designing antibodies that can either selectively block the inhibitory signal of LILRB3 without impairing LILRA6, or conversely, exploit LILRA6 activation to stimulate anti-tumor myeloid activity. The industry is progressing toward highly selective monoclonal antibodies and bispecific formats capable of remodeling the tumor microenvironment (TME).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biotech / Academic Consortia | Solid Tumors, AML, Autoimmune Disorders | Selectivity Screening (Need high-purity LILRA6 vs. LILRB3 ECD-Fc proteins) |
| Bispecific / Multi-specific | Immuno-oncology Therapeutics Developers | Refractory Solid Tumors | Dual-targeting validation (Requires high-purity LILRA6 and tumor-associated antigens) |
| Cell Therapies (CAR-Myeloid) | Next-Gen Cell Therapy Pioneers | Advanced Malignancies | Stable expression validation (Need Lentivirus for stable cell line construction) |